Robert Burton Moore Jr., a director at ROCKY BRANDS, INC. (), recently reported transactions involving the company’s common stock. On August 5, 2026, Mr. Moore sold shares totaling $149,190. Two days later, on August 7, 2026, he exercised stock options
Sterling A. Spainhour Jr., Executive Vice President and Chief Legal Officer at Southern Company (), sold 3,333 shares of the company’s common stock on August 6, 2026. The shares were sold at a price of $94.02 each, totaling approximately $313,368.
Wealthy American families are increasingly seeking to book assets outside the United States — a shift so pronounced that one of Citi’s top wealth executives says she’s never seen anything like it in her
Timothy Archer, President and CEO of Lam Research Corp. (), sold 30,000 shares of the company’s common stock on August 6, 2026, for a total value of $9,000,000. The shares were sold at a price of $300 per share. The
Blaine Scott White, a Director and 10% Owner of NEW PEOPLES BANKSHARES INC (), acquired 1,716 shares of the company’s common stock on August 5, 2026. The shares were purchased at a price of $4.35 each, totaling $7,464. The purchase comes
Rajesh Pankaj, Chief Technology Officer at InterDigital, Inc. (), sold 1,500 shares of the company’s common stock on August 5, 2026. The shares were sold at a price of $324.88 per share, resulting in a total transaction value of $487,320.
Storytelling about risk is a tricky subject. We tend to reach for metaphors we hope improve understanding. Instead, we may just be adding to the problem. “Going rogue” is the latest iteration—a way of
Phillip Frost, a director and 10% owner of Cocrystal Pharma, Inc. (), purchased shares of the company’s common stock on August 5, 2026. Dr. Frost acquired 10,000 shares at a weighted average price of $0.9816 per share, with individual transaction
Micah R. Conrad, Executive Vice President and Chief Operating Officer at OneMain Holdings, Inc. (), sold shares of the company’s common stock totaling $327,005 on August 4, 2026. The transaction involved the disposition of 5,000 shares. The shares were
Blake Borgeson, a director at Recursion Pharmaceuticals (), sold 30,000 shares of the company’s Class A Common Stock on August 4, 2026, for a total value of $97,500. The shares were sold at a price of $3.25 per share. This
